Introduction
Gastrointestinal stromal tumors (GIST) are the most common gastrointestinal mesenchymal tumors. [1] GISTs are immunoreactive to CD117 and DOG1 in >95% of cases. [2] Molecular studies have shown that ~85% GISTs possess mutually exclusive gain-of-function mutations in either the KIT or PDGFRA gene leading to the pathogenesis of GIST through the activation of KIT downstream signals pathways. [2, 3] KIT, a member of the receptor tyrosine kinases where exon 11 encodes for the Juxtamembrane region, exon 9 for part of the extracellular domain, exon 13 and exon 17 for the intracellular kinases, ATP binding domain and phosphotransferase domain, respectively. [3] The range of mutations reported in the literature with the most common mutations identified in exon 11 is 20%-92% [4] followed by exon 9 in 3%-18% [5, 6] with a lower frequency of around 0.6%-4% in exons 13 and 17. [6] Currently, treatment with Imatinib (Gleevec ® ; Novartis, Basel, Switzerland) is the standard first-line of therapy for patients with GIST. Patients with exon 11 mutations exhibit maximal benefit from prolonged adjuvant treatment, exon 9 mutations may benefit with the escalation of Imatinib doses and wild-type GISTs demonstrate a limited response to Imatinib. [7] Therefore, genetic testing is emerging as a predictive biological marker that will aid clinicians in decision making while treating different subsets of GIST. There is a paucity of molecular data on Indian GISTs as case reports, [8] short series [9] our clinical data. [10, 11] The primary aim of this study was to determine the frequency of KIT mutations in a large cohort of GIST patients. This is the largest study from India covering all hot spot regions (exons 11, 9, 13, and 17) of the KIT gene.
Materials and Methods

Histopathologic and immunohistochemistry review
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For reprints contact: reprints@medknow.com polymerase (Takara, Clontech). The PCR conditions were: 95°C for 15 min followed by 40 cycles of 95°C for 30 s, 56°C for 1 min, 72°C for 1 min, and final extension at 72°C for 10 min. PCR products were analyzed in 1.5% agarose gel and subjected to purification using EXO-SAP IT (USB, Affymetrix).
Gene sequencing on 3500 genetic analyzer
The purified products were bidirectionally sequenced using Big Dye version 3.1 cycle sequencing kit (Applied Biosystems, USA). Big Dye X-Terminator kit was used for purification followed by loading on ABI 3500 Genetic Analyzer for capillary electrophoresis (Applied Biosystems, Foster City, CA, USA).
Sequence analysis
SeqScape
® (Applied Biosystems) and Chromas Lite software were used for sequence analysis using KIT reference sequence (Gene ID 3815). Mutations were reported as per Human Genome Variation Society (www.hgvs.org) recommendations. The dbSNP, COSMIC, and Ensembl genome databases were referred.
Statistical analysis
SPSS statistical software version 16.0 (IBM,NY,USA) was used for correlation of the KIT mutation status with clinicopathological features. Chi-square test with the value of P < 0.05 was considered statistically significant.
Results
Among 114 confirmed GIST cases 100 were subjected to molecular analysis. and in one case exact small intestinal location was unknown), colon (2%), and rectum (6%). Extra-gastrointestinal GIST was observed in 9% of cases at following sites: retroperitoneum (3%), mesentery (3%), omentum (2%), and pelvic cavity (1%). On histopathological evaluation, spindle, epithelioid, and mixed subtypes accounted for 75%, 19%, and 6% of the tumors, respectively. IHC evaluation revealed CD117 positivity in 98%, among CD117 negative cases one was negative for DOG-1; positive for CD34 [Table1] .
Genotype analysis
The tumor samples represented primary (73%), metastatic (21%), and local recurrence (5%) sites. In one case, primary and metastatic tumors both were analyzed. KIT mutations were seen in 70 (70%) cases involving exons 11 (57%), 9 (10%), 13 (3%), and 17 (1%). One case with double mutations of exons 11 and 13. A majority of mutations were heterozygous (n = 64, 91.4%). Homozygous mutations in 6 (8.6%); which was in exon 11 in 5 cases. (In-frame deletion [n = 3]; substitution [n = 2]) and exon 13 in 1 case with substitution mutation [ Table 2 ].
Exon 11 mutations
Exon 11 mutations were in 57% of cases [ Figure 2 ]. Exon 11 mutations were heterogeneous with in-frame deletion of 3-51 nucleotides (codons 550-576) in classic hot-spot region at the 5' end of the exon (codons 550-560). Double mutations were identified in 9 cases (16%), 8 within exon 11 (14.3%), exon 11 and 13 were involved in one case (1.8%). In all double mutations, one mutation was consistently a deletion, whereas the 2 nd mutation represented substitutions (n = 5), insertions (n = 2) and duplication (n = 1). Interestingly, 3 novel mutations were unraveled, i.e. Table 2] . One case with simultaneous mutations in exons 11 and 13 harbored in-frame deletion in exon 11; p.M552_K558del (c.1654_1 674delATGTATGAAGTACAGTGGAAG) and a novel substitution mutation; p.K642R (c.1925A>G) [ Figure 1d ] in exon 13 in a treatment-naive young male (35 years) GIST at gastric location, spindle morphology, and immunoreactivity to CD117 and DOG1. The substitution mutations were p.V559D (3/57; 5%), p.V560D (3/57; 5%), p.V559A (2/57; 3.5%), and 1 (1.8%) cases each with p.V560G, p.T574I, and p.L576P among this 9 were homozygous and 2 heterozygous. Insertion of 3 nucleotides, p.K558delinsBP (c.1673_1674insTCC), and duplication p.Y577_K580dup (c.1731_1742dupTTATGATCACAA) was seen 1 case (1.8%) each, respectively. The KIT exon 11 mutation was predominant in men (n = 40, 70.1%), in the stomach (n = 28, 49%) spindle histology (n = 46, 80.7%), and immunoreactivity to CD117 (n = 55, 98.2%) [Tables 2]. Gastric tumors showed deletions (54.5%) and duplications (100%), whereas small intestinal tumors mostly displayed substitution (40%) and insertion (100%) mutations.
Exon 9 mutations
Mutations were identified in 10 cases located in the small intestine with significant association (P = 0.004). One was located in the retroperitoneum. Ninety percent (9/10) tumors revealed internal tandem duplications (ITD) of 6 nucleotides (c.1504_1509 dup GCCTAT) causing duplication of Ala-Tyr at codons 502-503 [ Figure 3a ]. All were male predominant (8/10) with spindle cell morphology (6/10). One case with the insertion of 6 nucleotides (c.1509_1510insACCTAT) causing p.Y503_F504insTY [ Figure 3b ], was a novel mutation in a 70 years old man with duodenal GIST, epithelioid morphology, immunoreactive for CD117 and DOG1.
Exon 13 mutations
Three cases involving p.K642E mutation (c.1924A>G) [ Figure 4a ], 2/3 were in elderly men, at gastric, an anorectal site with mixed morphology. One was a double mutation in association with exon 11 [ Table 2 ].
Exon 17 mutation
A single case with p.N822K (c.2466T>A) [ Figure 4b ] was identified. The tumor originated in jejunum in an elderly man with spindle morphology.
Clinicopathological features of KIT-mutated cases (n = 70)
Age range was 23-79 (median-55 years) 61.4% (n = 43) cases were >50 years. Sex ratio was 2.7:1 (M-51; F-19). Small intestine (30/70; 42.8%) was the most common primary site followed by the stomach (29/70; 41.4%). Spindle, epithelioid, and mixed subtypes in 53 (75.7%), 13 (18.6%), and 4 (5.7%) cases, respectively. On IHC, 69 cases were positive for CD117 and/or DOG1, and in 1 case both were negative. However, CD34 was positive. Clinicopathological features had no significant correlation with the KIT mutation status.
Discussion
The frequency of KIT mutations in GIST is variable with 50%-92.9% in the Western countries [14] [15] [16] to 38.5%-84.2% in Asian regions. [5, [17] [18] [19] There are only 2 studies, and few case reports from India. [5, 8, 9] Cyriac et al. [9] retrospectively analyzed KIT exons 9 and 11 on 19 cases of metastatic GIST. Ahmad et al. [5] evaluated KIT exons 9, 11, and 13 in 70 patients diagnosed with GIST. The frequency of KIT mutations in our cohort was 70% (70/100) is the highest reported from India comparable to Western data. [15, 20, 21] An interesting observation in the present study is the documentation of mutations in exons 13, 17, and simultaneous mutations in exons 11 and 13. The variation in mutations frequency across literature stems from referral center bias, tumor tissue types, methodology, and analysis. [22] In concordance with published studies, the majority of exon 11 mutations were in the classic "hot-spot" region (codons 550-560), with remarkable heterogeneity. The incidence of ITD affecting 3' portion of exon 11 in our series was 1.8% lower than the reported rate of 11%-14%.
[4] The primary double KIT mutations which are quite rare may involve nucleotides within the same hotspot exon, which is considered to have an origin in a single mutagenic event or is characterized by losses or frameshift/stop codon mutations in the wild-type KIT allele of KIT-mutated GISTs. [23] Only 4 examples of double primary mutations involving different hotspot exons of KIT in treatment-naive GISTs are available in literature till date, of which 3 involved exons 9 and 11, [24, 25] one in exons 13 and 17. [26] A novel occurrence of primary double mutation in exons 11 and 13, in a therapy-naive patient with gastric GIST was reported in this study. Prognostic value of KIT mutations has conflicting reports. Patients with in-frame deletions (codons 557-558), Indels have been associated with aggressive behavior as compared to substitutions. [4] Lasota et al. [27] have reported a risk of progressive disease and malignant clinical behavior with homozygous exon 11 mutations as compared to heterozygous and are considered as an adverse prognostic marker in GIST. Duplications at 3' portion of exon 11 have been linked to gastric GISTs which are relatively indolent. [28] Prognostic significance of primary double KIT mutations is not fully recognized on account of their rarity; however, cases involving diverse hotspot exons seem to confer an aggressive behavior or a high-risk phenotype. [23] The frequency of exon 9 mutation was 10% which is in the range of 5%-18% in the literature [5] with a distinct subset of GIST localized to small intestine characterized by an identical duplication (codons 502-503). A novel variant Y503_F504insTY (1509_1510insACCTAT) in a duodenal GIST was reported in this study. The incidence of exons 13 (p.K642E) and 17 (p.N822K) mutations in our series were in the range as previously published in the literature. A few reports indicate dismal prognosis for exon 13 mutated gastric tumors and exon 17 mutations implications are unknown.
Conclusions
The present study is the first largest comprehensive analysis of all 4 exons of KIT in Indian patients with GIST with important caveats. Not only common, well-described KIT mutations identified but also rare double mutations, novel alterations were reported in this cohort. The clinical implications associated with these mutations have already been published by this group. [10, 11] 
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The support from Molecular Pathology, Surgical Pathology and Medical Oncology GI Unit is acknowledged. Dear Editor, The Sokal and Hasford scores were developed in the chemotherapy and interferon era (preimatinib era) and are used as prognostic indicators in patients with chronic myeloid leukemia (CML). At present, CML is largely prognosticated on the basis of Hasford score at the time of presentation and subsequently by response to therapy which is ideally monitored by assessing cytogenetic and molecular response. However, in a resource poor setting, serial monitoring by assessing cytogenetic and molecular response is not feasible. Hence, the dependence on scoring systems do not use cytogenetic and molecular response criteria. European Treatment and Outcome Study (EUTOS) scoring system was developed recently to assess prognosis in CML patients on imatinib. We compared the applicability of Hasford score and EUTOS score in Indian patients with chronic phase CML on imatinib therapy. We compared the EUTOS and Hasford prognostic scores in predicting 3-, 6-, and 12-month hematologic remission in patients of chronic phase CML (CP-CML) on imatinib. Seventy-five patients of CML-CP were enrolled, of which 52 patients were taken prospectively and 23 retrospectively. The Hasford score and EUTOS score were calculated at admission and compared with hematologic remission at 3 months, 6 months, and 12 months. The Hasford score for all patients was calculated based on age, spleen size, basophils, eosinophils, blast percentage, and platelet count at diagnosis. GATGAGATTGGCATGGCTTT  432  R1  CTCAAGTTGGGGGACAAAAA  ACTNB  F2  CTGTGGCATCCACGAAACTA  323  R2  AGTCCGCCTAGAAGCATTTG  KIT exon 9  F1  CCA CAT CCC AAG TGT TTT ATG  352  F2  CCC CTC CTA GAG TAA GCC AGG GCT T  R  GGT GTG ATG CAT GTA TTA CCA G  KIT exon 11  F  GAT GAT TCT GAC CTA CAA AT  299  R1  AGG AAG CCA CTG GAG TTC CTT  R2  CCC CGT CAC TGT TAT GTG TAC CCA  KIT exon 13  F1  GTA TGG TAC TGC ATG CGC TT  294  F2 GCT TGA CAT CAG TTT GCC AG R GAG AAC AAC AGT CTG GGT AA KIT exon 17  F  TTCACTCTTTACAAGTTAAAATG  212  R1  GAAACTAAAAATCCTTTGCAG  R2 GGA CTG TCA AGC AGA GAA TG F=Forward, R=Reverse
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